Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

VHL mutation

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

›

VHL mutation	Neuroendocrine Tumor	VHL mutation	Neuroendocrine Tumor	belzutifan Sensitive: A1 - Approval belzutifan Sensitive : A1	belzutifan Sensitive: A1 - Approval belzutifan Sensitive : A1
VHL mutation	CNS Tumor	VHL mutation	CNS Tumor	belzutifan Sensitive: A1 - Approval belzutifan Sensitive : C1	belzutifan Sensitive: A1 - Approval belzutifan Sensitive : C1
VHL mutation	Renal Cell Carcinoma	VHL mutation	Renal Cell Carcinoma	belzutifan Sensitive: A1 - Approval belzutifan Sensitive : C1	belzutifan Sensitive: A1 - Approval belzutifan Sensitive : C1
VHL mutation	Clear Cell Renal Cell Carcinoma	VHL mutation	Clear Cell Renal Cell Carcinoma	belzutifan Sensitive: C1 - Off-label belzutifan Sensitive : C1	belzutifan Sensitive: C1 - Off-label belzutifan Sensitive : C1
VHL mutation	Glioblastoma	VHL mutation	Glioblastoma	belzutifan Sensitive: C1 - Off-label belzutifan Sensitive : C1	belzutifan Sensitive: C1 - Off-label belzutifan Sensitive : C1
VHL mutation	Clear Cell Renal Cell Carcinoma	VHL mutation	Clear Cell Renal Cell Carcinoma	MK-3795 Sensitive: C2 – Inclusion Criteria MK-3795 Sensitive : C2	MK-3795 Sensitive: C2 – Inclusion Criteria MK-3795 Sensitive : C2
VHL mutation	Neuroendocrine Tumor	VHL mutation	Neuroendocrine Tumor	MK-3795 Sensitive: C3 – Early Trials MK-3795 Sensitive : C3	MK-3795 Sensitive: C3 – Early Trials MK-3795 Sensitive : C3
VHL mutation	Clear Cell Renal Cell Carcinoma	VHL mutation	Clear Cell Renal Cell Carcinoma	pazopanib Resistant: C3 – Early Trials pazopanib Resistant : C3	pazopanib Resistant: C3 – Early Trials pazopanib Resistant : C3
VHL mutation	Renal Cell Carcinoma	VHL mutation	Renal Cell Carcinoma	everolimus Sensitive: C3 – Early Trials everolimus Sensitive : C3	everolimus Sensitive: C3 – Early Trials everolimus Sensitive : C3
VHL mutation	Clear Cell Renal Cell Carcinoma	VHL mutation	Clear Cell Renal Cell Carcinoma	VEGFR inhibitor Sensitive: C3 – Early Trials VEGFR inhibitor Sensitive : C3	VEGFR inhibitor Sensitive: C3 – Early Trials VEGFR inhibitor Sensitive : C3
VHL mutation	Renal Cell Carcinoma	VHL mutation	Renal Cell Carcinoma	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
VHL mutation	HER2 Positive Breast Cancer	VHL mutation	HER2 Positive Breast Cancer	trastuzumab Sensitive: C3 – Early Trials trastuzumab Sensitive : C3	trastuzumab Sensitive: C3 – Early Trials trastuzumab Sensitive : C3
VHL mutation	Cholangiocarcinoma	VHL mutation	Cholangiocarcinoma	sunitinib Sensitive: C4 – Case Studies sunitinib Sensitive : C4	sunitinib Sensitive: C4 – Case Studies sunitinib Sensitive : C4
VHL mutation	Renal Cell Carcinoma	VHL mutation	Renal Cell Carcinoma	doxorubicin hydrochloride Sensitive: D – Preclinical doxorubicin hydrochloride Sensitive : D	doxorubicin hydrochloride Sensitive: D – Preclinical doxorubicin hydrochloride Sensitive : D